---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-015599"
form_type: "8-K"
ticker: "AIXC"
cik: "0001460702"
company_name: "AIxCrypto Holdings, Inc."
filed_at: "2023-05-05T23:59:59+00:00"
generated_at: "2026-06-15T16:28:15.929648+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Qualigen Therapeutics regains Nasdaq compliance after filing overdue 10-K

## Summary
- Received delisting notice on April 20, 2023 for late filing of 2022 Form 10-K.
- Filed the delinquent Form 10-K on May 2, 2023.
- On May 4, 2023, Nasdaq confirmed compliance with Listing Rule 5250(c)(1); matter closed.

## SEC filing metadata
- accession: 0001493152-23-015599
- form_type: 8-K
- ticker: AIXC
- cik: 0001460702
- company_name: AIxCrypto Holdings, Inc.
- filed_at: 2023-05-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1460702/000149315223015599/0001493152-23-015599-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1460702/000149315223015599/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-015599
- JSON: https://secwatch.observer/filing/0001493152-23-015599.json
- Plain text: https://secwatch.observer/filing/0001493152-23-015599.txt

## Key facts
- Listing & Compliance Notices
  AIxCrypto Holdings, Inc. received a nasdaq compliance regained notice regarding late filing (rules 5250(c)(1)).
  - Exchange: nasdaq
  - Notice: compliance regained
  - Deficiency: late filing
  - Rules: 5250(c)(1)
  source text: May 4, 2023 that it had regained compliance with Nasdaq’s listing rule 5250(c)(1) as a result thereof and that the matter is now closed. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: May 5, 2023 By: /s/ Michael S. Poirier Michael S. Poirier, Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1460702/000149315223015599/0001493152-23-015599-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.